The phase IIIb trial compared Feraccru against Ferinject in 242 inflammatory bowel disease (IBD) patients whose iron deficiency anaemia (IDA) and haemoglobin (Hb) measurements are as low as
The post Shield Therapeutics’Feraccru meets endpoints in anaemia trial appeared first on Pharmaceutical Business review.
Original Article: Shield Therapeutics’Feraccru meets endpoints in anaemia trial